Valuation: Monopar Therapeutics Inc.

Market Cap 767M 664M 622M 568M 1.07B 73.13B 1.09B 7.29B 2.86B 36.6B 2.88B 2.82B 122B P/E 2026 *
-49.6x
P/E 2027 * -33x
Enterprise Value 648M 562M 526M 480M 903M 61.82B 918M 6.17B 2.42B 30.94B 2.43B 2.38B 103B EV / Sales 2026 *
-
EV / Sales 2027 * 41.3x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-3.38%
Current month+5.64%
1 month+7.37%
3 months+74.69%
6 months+92.73%
Current year+75.28%
1 week 113.25
Extreme 113.25
124.82
1 month 97.93
Extreme 97.93
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 29.18
Extreme 29.18
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2014
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-3.38%+265.22%+3,124.23% 767M
-0.72%+3.41%+6.32%+16.27% 49.54B
-0.69%+6.25%+492.36%+585.40% 44.06B
+0.08%+11.23%+23.99%+81.74% 40.85B
+0.76%+6.85%+35.40%+10.92% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
-0.41%+4.08% - - 16.78B
+0.51%+5.29%+34.62%+126.87% 16.9B
-0.20%+1.57%+5.49%+21.35% 14B
+1.81%+20.45%+89.35%+31.49% 13.46B
Average +0.42%+267.21%+108.95%+450.28% 27.07B
Weighted average by Cap. +0.56%+296.37%+108.01%+147.66%

Financials

2026 *2027 *
Net sales - 15.84M 13.73M 12.85M 11.73M 22.07M 1.51B 22.44M 151M 59.04M 756M 59.48M 58.18M 2.52B
Net income -20.16M -17.47M -16.36M -14.92M -28.08M -1.92B -28.56M -192M -75.14M -962M -75.7M -74.05M -3.21B -35.74M -30.97M -28.99M -26.45M -49.78M -3.41B -50.62M -340M -133M -1.71B -134M -131M -5.69B
Net Debt -119M -103M -96.19M -87.77M -165M -11.31B -168M -1.13B -442M -5.66B -445M -435M -18.88B -112M -97.35M -91.14M -83.16M -156M -10.71B -159M -1.07B -419M -5.36B -422M -413M -17.89B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
11/08/26 US$114.46 -1.62% 210,762
10/08/26 US$116.35 -2.40% 280,348
07/08/26 US$119.21 -0.83% 223,298
06/08/26 US$120.21 +0.82% 285,799
05/08/26 US$119.23 +0.65% 182,731
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
114.46USD
Average target price
116.85USD
Spread / Average Target
+2.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock